アレル固有の阻害剤は,捕捉メカニズムによって変異したKRAS G12Cを無効化する
Piro Lito1, Martha Solomon2, Lian-Sheng Li3
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. rosenn@mskcc.org litop@mskcc.org.
Science (New York, N.Y.)
|February 4, 2016
まとめ
新しい治療法では,不活性状態のタンパク質を捕まえてKRAS (G12C) 信号伝達を阻害し,不活性なグアノシントリフォスファターゼ (GTPase) 活性を必要とします. このメカニズムは,KRAS ((G12C) 誘発がんの治療に新しいアプローチを提供します.
科学分野:
- 腫瘍学
- 分子生物学
- 生物化学
背景:
- KRASオンコプロテインは,無効化されたグアノシントリフォスファターゼ (GTPase) の活動により構成的に活性化されます.
- 非活性なKRAS構造を標的とする薬は,一般的に無効とみなされる.
- KRAS変異,特にG12Cは,様々な癌の共通要因です.
研究 の 目的:
- KRAS ((G12C) 信号伝達と癌細胞の増殖を抑制する新しいメカニズムを解明する.
- 薬効性におけるGTPase活性と核酸交換の役割を調査する.
- KRAS ((G12C)) 誘発がんに対する標的治療の開発の根拠を提供すること.
主な方法:
- 癌細胞におけるKRAS (G12C) 信号伝達の薬剤阻害を研究した.
- 薬剤の有効性のためにGTPaseの活性度の必要性を評価した.
- 薬効性に対するヌクレオチド交換因子の影響を調べた.
- KRAS ((G12C) 抑制に対するニュクレオチド交換活性調節の効果を評価した.
主要な成果:
- 薬剤に結合したKRAS ((G12C) は不活性状態に閉じ込められ,不活性なGTPaseの活性が抑制される必要があります.
- GTPaseの活性が欠如している変異体や,ヌクレオチドの交換を促す変異体は,薬の効能を低下させる.
- 核酸交換の抑制はKRAS ((G12C) 抑制を強化し,増強は減少させた.
- KRAS ((G12C) は癌細胞でニュクレオチドサイクルを繰り返します.
結論:
- KRAS ((G12C) 阻害剤は,オンコタンパク質の不活性なGDP結合状態を閉じ込めて作用する.
- 無傷のGTPase活性と抑制された核酸交換は,効果的なKRAS (G12C) 抑制に不可欠です.
- これらの発見は,KRAS (G12C) 誘発の悪性腫瘍を標的とした新しい治療法の開発に道を開きます.
さらに関連する動画
07:23Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
1.3K
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.8K
関連する概念動画
02:34Inhibition of Cdk Activity
6.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
02:38The Ras Gene
7.5K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
7.5K
01:16In-vitro Mutagenesis
17.6K
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
17.6K
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K